SubHero Banner

Identifying and treating those most at risk

84 million adults in the U.S. have prediabetes — blood sugar levels that are elevated, but not high enough to indicate diabetes. If not addressed, prediabetes can develop into type 2 diabetes (T2D). 

With so many at risk, there’s a need to focus on those individuals at highest risk of near-term progression to T2D. 

To address this issue, OptumLabs facilitated collaboration between teams from Tufts Medical Center and AMGA to develop a model that uses OptumLabs data to predict individual risk of developing T2D within three years. 

It also provides an individualized estimate of the benefit of the two interventions — an intensive lifestyle program or the glucose management medication metformin — with the goal of connecting those at highest risk to prevention efforts. 

The model is being piloted at Premier Medical Associates with strikingly positive results. AMGA is working with Mercy and Interopion to create a cloud-hosted version of the model that can be incorporated into any leading Electronic Health Record.

At the patient level, this model informs shared decision-making. At the population level, it helps provider organizations risk-stratify people with prediabetes.

Color Block


A unique model with potential for impact

Listen to experts discuss what makes this model different and its potential to scale nationally.

Speakers: John Cuddeback, MD, PhD, Chief Medical Informatics Officer at AMGA; David Kent, MD, MS, Professor of Medicine and Director of the PACE Center at Tufts Medical Center; and Frank Colangelo, MD, MS-HQS, Chief Quality Officer at Premier Medical Associates.